SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 139 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $495,684 | -11.0% | 34,138 | +28.2% | 0.00% | – |
Q2 2023 | $557,157 | +22.1% | 26,620 | +23.2% | 0.00% | – |
Q1 2023 | $456,403 | -12.7% | 21,610 | +5.2% | 0.00% | – |
Q4 2022 | $523,023 | +8.6% | 20,551 | +2.6% | 0.00% | – |
Q3 2022 | $481,417 | +22.4% | 20,034 | -2.0% | 0.00% | – |
Q2 2022 | $393,169 | +17.2% | 20,435 | +5.9% | 0.00% | – |
Q1 2022 | $335,382 | -34.1% | 19,297 | -17.0% | 0.00% | – |
Q4 2021 | $509,000 | +11.6% | 23,256 | -2.6% | 0.00% | – |
Q3 2021 | $456,000 | +3.9% | 23,884 | -6.6% | 0.00% | – |
Q2 2021 | $439,000 | +8.9% | 25,570 | +42.0% | 0.00% | – |
Q1 2021 | $403,000 | +8.9% | 18,007 | +8.2% | 0.00% | – |
Q4 2020 | $370,000 | +52.9% | 16,637 | +1.5% | 0.00% | – |
Q3 2020 | $242,000 | +2.1% | 16,391 | 0.0% | 0.00% | – |
Q2 2020 | $237,000 | +50.0% | 16,391 | +13.6% | 0.00% | – |
Q1 2020 | $158,000 | +36.2% | 14,435 | +9.2% | 0.00% | – |
Q4 2019 | $116,000 | +2.7% | 13,214 | -9.6% | 0.00% | – |
Q3 2019 | $113,000 | -16.9% | 14,621 | 0.0% | 0.00% | – |
Q2 2019 | $136,000 | +2620.0% | 14,621 | +1922.3% | 0.00% | – |
Q2 2018 | $5,000 | -96.7% | 723 | -93.2% | 0.00% | – |
Q1 2018 | $151,000 | +504.0% | 10,566 | +266.9% | 0.00% | – |
Q4 2017 | $25,000 | +212.5% | 2,880 | +297.8% | 0.00% | – |
Q3 2017 | $8,000 | +700.0% | 724 | +670.2% | 0.00% | – |
Q2 2017 | $1,000 | 0.0% | 94 | -3.1% | 0.00% | – |
Q1 2017 | $1,000 | 0.0% | 97 | 0.0% | 0.00% | – |
Q4 2016 | $1,000 | – | 97 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |